Director Teresa S. Van De Bogart filed a Form 4 with the SEC on August 24, 2026, reporting the disposition of 57,362 shares of RE/MAX Holdings, Inc. Class A Common Stock in connection with the company's merger with The Real Brokerage Inc., reducing her …
REGENXBIO Inc. filed a current report on August 24, 2026, disclosing that the U.S. Food and Drug Administration placed the company's Investigational New Drug application for its Phase I/II/III trial of RGX-121 on clinical hold, and that the company does not expect to resubmit …
A statement of changes in beneficial ownership filed on August 24, 2026, disclosed that Erik Olsson, a director at Herc Holdings Inc., purchased 3,085 shares of the company's common stock on August 21, 2026.
LaJuana S. Wilcher, a director of Federal Agricultural Mortgage Corporation, filed a statement of changes in beneficial ownership on August 24, 2026, reporting a disposition of Class C Non-Voting Common Stock on August 21, 2026.
Winnie Ling, Head of Legal and People at Blend Labs, Inc. (NYSE:BLND), filed a Form 4 on August 24, 2026, disclosing two separate RSU vesting transactions dated August 20, 2026, along with shares withheld for tax purposes.
Matthew Christopher Thomson, Head of Revenue at Blend Labs, Inc., filed a Form 4 on August 24, 2026, disclosing transactions in Class A Common Stock dated August 20, 2026, involving the vesting of restricted stock units and the withholding of shares for tax obligations.
A Form 4 filed on August 24, 2026 disclosed that Nima Ghamsari, Director and Head of Blend at Blend Labs, Inc. (NYSE:BLND), reported restricted stock unit vestings and a share withholding transaction dated August 20, 2026.
Michael Marinaro, Executive Vice President and President of MedSurg and Americas at Medtronic plc, filed a Form 4 on August 24, 2026, reporting a disposition of ordinary shares on August 20, 2026, related to restricted stock unit vesting.
A Form 4 filed on August 24, 2026 with the U.S. Securities and Exchange Commission discloses that Ernest W. Marshall, Jr., a director of LSI Industries Inc. (NASDAQ:LYTS), purchased a total of 2,000 common shares on August 24, 2026.
Jeffrey C. Kunins, Chief Product Officer and Chief Technology Officer of Axon Enterprise, Inc., filed a Form 4 on August 24, 2026, disclosing the sale of common stock on August 21, 2026, pursuant to a Rule 10b5-1 trading plan.